Introduction
Edited by: Ingo Drexler, Heinrich Heine University, GermanyReviewed by: Kai Wu, Moderna Inc., United States; Nawamin Pinpathomrat, Prince of Songkla University, Thailand; Gyanendra Gongal, World Health Organization - Regional Office for South-East Asia, IndiaThis article was submitted to Viral Immunology, a section of the journal Frontiers in ImmunologyThis phase I study explored the immunogenicity and reactogenicity of accelerated, Q7 fractional, intradermal vaccination regimens for COVID-19.